Chia-Jui Yen
- Molecular Biology top 10%
- Oncology top 5%
- Hepatology top 1%
- Cancer Research top 5%
- Pulmonary and Respiratory Medicine top 5%
- Co-authors
- Baek‐Yeol RyooMasatoshi KudoPaolo AbadaHyun Cheol ChungAndrew X. ZhuTakuji OkusakaJoon Oh ParkLing Yang
- Topics
- Hepatocellular Carcinoma Treatment and Prognosis (8 papers)Liver physiology and pathology (6 papers)MicroRNA in disease regulation (5 papers)
- Cited by
- HepatologyCancer ResearchOncology
- Partner nations
- TaiwanUnited StatesSouth Korea
In The Last Decade
Chia-Jui Yen
63 papers receiving 2.7k citations
Hit Papers
Peers
Comparison fields: 5 of 108
- Molecular Biology 1.1k
- Oncology 955
- Hepatology 777
- Cancer Research 613
- Pulmonary and Respiratory Medicine 530
Countries citing papers authored by Chia-Jui Yen
This map shows the geographic impact of Chia-Jui Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chia-Jui Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chia-Jui Yen more than expected).
Fields of papers citing papers by Chia-Jui Yen
This network shows the impact of papers produced by Chia-Jui Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chia-Jui Yen. The network helps show where Chia-Jui Yen may publish in the future.
Co-authorship network of co-authors of Chia-Jui Yen
This figure shows the co-authorship network connecting the top 25 collaborators of Chia-Jui Yen. A scholar is included among the top collaborators of Chia-Jui Yen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chia-Jui Yen. Chia-Jui Yen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 27 | |
| 2 | 22 | |
| 3 | 21 | |
| 4 | 15 | |
| 5 | 7 | |
| 6 | 11 | |
| 7 | 51 | |
| 8 | 14 | |
| 9 | 58 | |
| 10 | 132 | |
| 11 | 17 | |
| 12 | 20 | |
| 13 | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialbreakdown → | 634 |
| 14 | 25 | |
| 15 | 34 | |
| 16 | 48 | |
| 17 | 97 | |
| 18 | 21 | |
| 19 | 49 | |
| 20 | 163 |
About Chia-Jui Yen
Chia-Jui Yen is a scholar working on Hepatology, Oncology and Otorhinolaryngology, having authored 63 papers that have together received 2.7k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Liver physiology and pathology (6 papers) and MicroRNA in disease regulation (5 papers). The work is most often cited by research in Hepatology (777 citations), Cancer Research (613 citations) and Oncology (955 citations). Chia-Jui Yen has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include Baek‐Yeol Ryoo, Masatoshi Kudo, Paolo Abada, Hyun Cheol Chung, Andrew X. Zhu, Takuji Okusaka, Joon Oh Park, Ling Yang, Jean-Frédéric Blanc and Davide Pastorelli. Their work appears in journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Molecular Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.